Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Siltuximab + Spartalizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Siltuximab||Sylvant||CNTO 328|CNTO328||Sylvant (siltuxmab) is an anti-IL-6 chimeric monoclonal antibody, which inhibits IL6 signaling and may lead to decreased tumor cell growth (PMID: 26170629, PMID: 26744529). Sylvant (siltuximab) is FDA approved for patients with multicentric Castleman's disease who do not have HIV or HHV-8 (FDA.gov).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 148 PD-L1/PD-1 antibody 93||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04191421||Phase Ib/II||Siltuximab + Spartalizumab||Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer||Recruiting||USA||0|